The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program

Sherita Hill Golden, Catherine Kim, Elizabeth Barrett-Connor, Bin Nan, Shengchun Kong, Ronald Goldberg

Research output: Contribution to journalArticle

Abstract

Objective It is unclear how lipids change in response to lifestyle modification or metformin among postmenopausal glucose intolerant women using and not using hormone therapy (HT). We examined the one-year changes in lipids among postmenopausal, prediabetic women in the Diabetes Prevention Program (DPP), and whether changes were mediated by sex hormones. Materials/Methods We performed a secondary analysis of a randomized controlled trial of 342 women who used HT at baseline and year 1 and 382 women who did not use HT at either time point. Interventions included intensive lifestyle (ILS) with goals of weight reduction of at least 7% of initial weight and 150 minutes per week of moderate intensity exercise, or metformin or placebo administered 850 mg up to twice a day. Women were not randomized to HT. Main outcome measures were changes between baseline and study year 1 in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Results Compared to placebo, both ILS and metformin significantly reduced LDL-C and raised HDL-C among HT users, changes partially explained by change in estradiol and testosterone but independent of changes in waist circumference and 1/fasting insulin. In contrast, DPP interventions had no effect on LDL-C and HDL-C among non-HT users. ILS significantly lowered triglycerides among non-users but did not significantly change triglycerides among HT users. Metformin did not significantly change triglycerides among non-users but increased triglycerides among HT users. Conclusions The beneficial effects of ILS and metformin on lowering LDL-C and raising HDL-C differ depending upon concurrent HT use.

Original languageEnglish (US)
Pages (from-to)1313-1322
Number of pages10
JournalMetabolism
Volume62
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Hormones
Lipids
Glucose
Metformin
Life Style
LDL Cholesterol
HDL Cholesterol
Triglycerides
Therapeutics
Placebos
Gonadal Steroid Hormones
Waist Circumference
Testosterone
Weight Loss
Estradiol
Fasting
Randomized Controlled Trials
Outcome Assessment (Health Care)
Exercise
Insulin

Keywords

  • Hormone therapy
  • Lifestyle intervention
  • Lipids
  • Sex hormones
  • Women

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. / Golden, Sherita Hill; Kim, Catherine; Barrett-Connor, Elizabeth; Nan, Bin; Kong, Shengchun; Goldberg, Ronald.

In: Metabolism, Vol. 62, No. 9, 09.2013, p. 1313-1322.

Research output: Contribution to journalArticle

Golden, Sherita Hill ; Kim, Catherine ; Barrett-Connor, Elizabeth ; Nan, Bin ; Kong, Shengchun ; Goldberg, Ronald. / The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. In: Metabolism. 2013 ; Vol. 62, No. 9. pp. 1313-1322.
@article{0f595961ca2d4c449a9fde408ead6df0,
title = "The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program",
abstract = "Objective It is unclear how lipids change in response to lifestyle modification or metformin among postmenopausal glucose intolerant women using and not using hormone therapy (HT). We examined the one-year changes in lipids among postmenopausal, prediabetic women in the Diabetes Prevention Program (DPP), and whether changes were mediated by sex hormones. Materials/Methods We performed a secondary analysis of a randomized controlled trial of 342 women who used HT at baseline and year 1 and 382 women who did not use HT at either time point. Interventions included intensive lifestyle (ILS) with goals of weight reduction of at least 7{\%} of initial weight and 150 minutes per week of moderate intensity exercise, or metformin or placebo administered 850 mg up to twice a day. Women were not randomized to HT. Main outcome measures were changes between baseline and study year 1 in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Results Compared to placebo, both ILS and metformin significantly reduced LDL-C and raised HDL-C among HT users, changes partially explained by change in estradiol and testosterone but independent of changes in waist circumference and 1/fasting insulin. In contrast, DPP interventions had no effect on LDL-C and HDL-C among non-HT users. ILS significantly lowered triglycerides among non-users but did not significantly change triglycerides among HT users. Metformin did not significantly change triglycerides among non-users but increased triglycerides among HT users. Conclusions The beneficial effects of ILS and metformin on lowering LDL-C and raising HDL-C differ depending upon concurrent HT use.",
keywords = "Hormone therapy, Lifestyle intervention, Lipids, Sex hormones, Women",
author = "Golden, {Sherita Hill} and Catherine Kim and Elizabeth Barrett-Connor and Bin Nan and Shengchun Kong and Ronald Goldberg",
year = "2013",
month = "9",
doi = "10.1016/j.metabol.2013.04.005",
language = "English (US)",
volume = "62",
pages = "1313--1322",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program

AU - Golden, Sherita Hill

AU - Kim, Catherine

AU - Barrett-Connor, Elizabeth

AU - Nan, Bin

AU - Kong, Shengchun

AU - Goldberg, Ronald

PY - 2013/9

Y1 - 2013/9

N2 - Objective It is unclear how lipids change in response to lifestyle modification or metformin among postmenopausal glucose intolerant women using and not using hormone therapy (HT). We examined the one-year changes in lipids among postmenopausal, prediabetic women in the Diabetes Prevention Program (DPP), and whether changes were mediated by sex hormones. Materials/Methods We performed a secondary analysis of a randomized controlled trial of 342 women who used HT at baseline and year 1 and 382 women who did not use HT at either time point. Interventions included intensive lifestyle (ILS) with goals of weight reduction of at least 7% of initial weight and 150 minutes per week of moderate intensity exercise, or metformin or placebo administered 850 mg up to twice a day. Women were not randomized to HT. Main outcome measures were changes between baseline and study year 1 in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Results Compared to placebo, both ILS and metformin significantly reduced LDL-C and raised HDL-C among HT users, changes partially explained by change in estradiol and testosterone but independent of changes in waist circumference and 1/fasting insulin. In contrast, DPP interventions had no effect on LDL-C and HDL-C among non-HT users. ILS significantly lowered triglycerides among non-users but did not significantly change triglycerides among HT users. Metformin did not significantly change triglycerides among non-users but increased triglycerides among HT users. Conclusions The beneficial effects of ILS and metformin on lowering LDL-C and raising HDL-C differ depending upon concurrent HT use.

AB - Objective It is unclear how lipids change in response to lifestyle modification or metformin among postmenopausal glucose intolerant women using and not using hormone therapy (HT). We examined the one-year changes in lipids among postmenopausal, prediabetic women in the Diabetes Prevention Program (DPP), and whether changes were mediated by sex hormones. Materials/Methods We performed a secondary analysis of a randomized controlled trial of 342 women who used HT at baseline and year 1 and 382 women who did not use HT at either time point. Interventions included intensive lifestyle (ILS) with goals of weight reduction of at least 7% of initial weight and 150 minutes per week of moderate intensity exercise, or metformin or placebo administered 850 mg up to twice a day. Women were not randomized to HT. Main outcome measures were changes between baseline and study year 1 in low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Results Compared to placebo, both ILS and metformin significantly reduced LDL-C and raised HDL-C among HT users, changes partially explained by change in estradiol and testosterone but independent of changes in waist circumference and 1/fasting insulin. In contrast, DPP interventions had no effect on LDL-C and HDL-C among non-HT users. ILS significantly lowered triglycerides among non-users but did not significantly change triglycerides among HT users. Metformin did not significantly change triglycerides among non-users but increased triglycerides among HT users. Conclusions The beneficial effects of ILS and metformin on lowering LDL-C and raising HDL-C differ depending upon concurrent HT use.

KW - Hormone therapy

KW - Lifestyle intervention

KW - Lipids

KW - Sex hormones

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84883203393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883203393&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2013.04.005

DO - 10.1016/j.metabol.2013.04.005

M3 - Article

C2 - 23660512

AN - SCOPUS:84883203393

VL - 62

SP - 1313

EP - 1322

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9

ER -